Therefore, targeting LL-37, MMP-9, and TAMs could be a potential anti-angiogenic drug target to suppress the local invasion of melanoma cells, which might improve the OS of melanoma patients in the future (Figure 6). This evidence concerns the gene CAMP and melanoma.